Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery.
Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery.
复制标题
DOI:
10.1016/j.chembiol.2013.01.011
复制
发表时间:
2013-03-21
影响因子:
--
通讯作者:
Freundlich JS
中科院分区:
文献类型:
--
作者:
Ekins S;Reynolds RC;Kim H;Koo MS;Ekonomidis M;Talaue M;Paget SD;Woolhiser LK;Lenaerts AJ;Bunin BA;Connell N;Freundlich JS
Identification of unique leads represents a significant challenge in drug discovery. This hurdle is magnified in neglected diseases such as tuberculosis. We have leveraged public high-throughput screening (HTS) data, to experimentally validate virtual screening approach employing Bayesian models built with bioactivity information (single-event model) as well as bioactivity and cytotoxicity information (dual-event model). We virtually screen a commercial library and experimentally confirm actives with hit rates exceeding typical HTS results by 1-2 orders of magnitude. The first dual-event Bayesian model identified compounds with antitubercular whole-cell activity and low mammalian cell cytotoxicity from a published set of antimalarials. The most potent hit exhibits the in vitro activity and in vitro/in vivo safety profile of a drug lead. These Bayesian models offer significant economies in time and cost to drug discovery.
登录
查看更多内容
DOI:
10.1073/pnas.1214188109
发表时间:
2012-10-02
影响因子:
11.1
作者:
Gold, Ben;Pingle, Maneesh;Nathan, Carl F.
通讯作者:
Nathan, Carl F.
影响因子:
3.7
作者:
Ekins, Sean;Freundlich, Joel S.
通讯作者:
Freundlich, Joel S.
影响因子:
5.6
作者:
Klon, Anthony E.;Lowrie, Jeffrey F.;Diller, David J.
通讯作者:
Diller, David J.
影响因子:
64.8
作者:
Gamo, Francisco-Javier;Sanz, Laura M.;Garcia-Bustos, Jose F.
通讯作者:
Garcia-Bustos, Jose F.
影响因子:
5.6
作者:
Ganguly, Milan;Brown, Nathan;Greenidge, Paulette A.
通讯作者:
Greenidge, Paulette A.